[1] Kano R,Hasegawa A.Historic topics on classification of Trichophyton mentagrophytes complex[J].Med Mycol J,2014,55(2):J73-77.
[2] Grser Y,Kuijpers AF,Presber W,et al.Molecular taxonomy of the Trichophyton rubrum complex[J].J Clin Microbiol,2000,38(9):3329-3336.
[3] de Hoog G.S,Guarro J,Gené J,et al.Atlas of clinical fungi:The ultimate benchtool for diagnostics4th ed.Utrecht:Westerdijk Fungal Biodiversity Institute,2014.
[4] Burzykowski T,Molenberghs G,Abeck D,et al.High prevalence of foot diseases in Europe:results of the Achilles Project[J].Mycoses,2003,46(11-12):496-505.
[5] Ilkit M,Durdu M.Tinea pedis:the etiology and global epidemiology of a common fungal infection[J].Crit Rev Microbiol,2015,41(3):374-388.
[6] Mahreen Ameen.Epidemiology of superficial fungal infections[J].Clinics in Dermatology,2010,28(2):197-201.
[7] Havlickova B,Czaika VA,Friedrich M.Epidemiological trends in skin mycoses worldwide[J].Mycoses,2008,51(Suppl 4):2-15.
[8] 杨利红,赵颖,严淑贤,等.上海新泾社区50岁以上居民足癣患病情况调查[J].中国真菌学杂志,2012,7(2):92-94.
[9] Watanabe S,Harada T,Hiruma M,et al.Epidemiological survey of foot diseases in Japan:results of 30,000 foot checks by dermatologists[J].J Dermatol,2010,37(5):397-406.
[10] Cheng S,Chong L.A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong[J].Chin Med J (Engl),2002,115(6):860-865.
[11] 费实,肖常青,李振洁,等.1999~2007年皮肤科门诊浅部真菌发病及镜检情况分析[J].中国真菌学杂志,2009,4(2):93-96,101.
[12] 王爱平,高露娟,席丽艳,等.手足癣治疗现状[J].中国真菌学杂志,2014,9(6):335-338.
[13] Wilson M,Bender S,Lynfield Y,et al.Two feet-one hand syndrome[J].J Am Podiatr Med Assoc,1988,78(5):250-253.
[14] Zhan P,Ge YP,Lu XL,et al.A case-control analysis and laboratory study of the two feet-one hand syndrome in two dermatology hospitals in China[J].Clin Exp Dermal,2010,35(5):468-472.
[15] 李春阳,李诚菊,徐永豪,等.2%酮康唑乳膏治疗浅部真菌病开放性、随机对照临床研究[J].中国真菌学杂志,2011,6(2):112-114.
[16] 王爱平,温海,赖维,等.1%联苯苄唑霜治疗足癣长期疗效观察[J].中国真菌学杂志,2008,3(4):224-227.
[17] 符美华,李岷,李若瑜,等.不同疗程1%卢立康唑乳膏治疗足癣的多中心、随机双盲对照研究[J].中华皮肤科杂志,2014,47(7):453-456.
[18] Jarratt M,Jones T,Adelglass J,et al.Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis:a phase 3,randomized,double-blind,vehicle-controlled study[J].J Drugs Dermatol,2014,13(7):838-846.
[19] Korting HC,Kiencke P,Nelles S,et al.Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen:results of a meta-analysis[J].Am J Clin Dermatol,2007,8(6):357-364.
[20] James IG,Loria-Kanza Y,Jones TC.Short-duration topical treatment of tinea pedis using terbinafine emulsion gel:results of a dose-ranging clinical trial[J].J Dermatolog Treat,2007,18(3):163-168.
[21] Li RY,Wang AP,Xu JH,et al.Efficacy and safety of 1 % terbinafine film-forming solution in Chinese patients with tinea pedis:a randomized,double-blind,placebo-controlled,multicenter,parallel-group study[J].Clin Drug Investig,2014,34(3):223-230.
[22] 李岷,顾军,毕志刚,等.1%盐酸布替萘芬乳膏治疗体股癣、足癣疗效观察[J].临床皮肤科杂志,2006,35(7):471-472.
[23] Gupta AK.Butenafine:an update of its use in superficial mycoses[J].Skin Therapy Lett,2002,7(7):1-2,5.
[24] Stein Gold LF,Parish LC,Vlahovic T,et L.Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis:pooled results from two multicenter,randomized,double-blind,vehicle-controlled trials[J].J Drugs Dermatol,2013,12(8):911-918.
[25] 王爱平,余进,陈伟,等.0.25%盐酸阿莫罗芬霜治疗足癣疗效和安全性评价[J].中国真菌学杂志,2007,2 (5):293-295.
[26] 王爱平,王端礼,虞瑞尧,等.1%环吡酮胺软膏治疗皮肤真菌病疗效观察[J].中华皮肤科杂志,1998,31 (5):337.
[27] Aly R,Fisher G,Katz I,et al.Ciclopirox gel in the treatment of patients with interdigital tinea pedis[J].Int J Dermatol,2003,42 (Suppl 1):29-35.
[28] 王英,沈永年,朱红梅,等.利拉萘酯乳膏治疗体股癣及足癣的多中心随机双肓对照观察[J].中华皮肤科杂志,2007,40(8):476-478.
[29] Gupta AK,Foley KA,Versteeg SG.New antifungal agents and new formulations against dermatophytes[J].Mycopathologia,2017,182(1-2):127-141.
[30] Tsunemi Y.Oral Antifungal drugs in the treatment of dermatomycosis[J].Med Mycol J,2016,57(2):J71-75.
[31] 张瑞峰,冉玉平,王鹏,等.1%萘替芬-0.25%酮康唑乳膏与2%酮康唑乳膏和1%特比萘芬乳膏的体外抗真菌谱及抗真菌活性对比研究[J].中国循证医学杂志,2011,11(5):508-514.